Hypofractionated Radiotherapy Combined with Chemotherapy Shows Promise for Small Cell Lung Cancer Treatment
A new phase III trial shows that a three-week hypofractionated radiotherapy schedule combined with chemotherapy offers similar survival rates and fewer side effects compared to traditional treatment for LS-SCLC patients.
A large-scale, randomized phase III study has demonstrated that a condensed three-week hypofractionated radiotherapy (HypoRT) regimen, administered alongside chemotherapy, yields survival outcomes comparable to the traditional six-week conventional radiotherapy (ConvRT) schedule in patients with limited-stage small cell lung cancer (LS-SCLC). Conducted across 16 hospitals in China and presented at the 2025 World Conference on Lung Cancer by the International Association for the Study of Lung Cancer, this research examined 530 patients allocated to either HypoRT (45 Gy delivered in 15 daily fractions over 3 weeks) or ConvRT (60 Gy over 30 fractions across 6 weeks), both combined with concurrent cisplatin/carboplatin-etoposide chemotherapy.
With a median follow-up of approximately 43.4 months, the study found median overall survival rates of 40.2 months for the HypoRT group and 47.9 months for the ConvRT group, showing no significant difference (HR=1.04; 95% CI, 0.81–1.33). Progression-free survival was also similar between the two schedules.
Importantly, patients undergoing the hypofractionated schedule experienced fewer severe side effects, including notable reductions in hematologic toxicity, lymphopenia, and radiation pneumonitis. Acute grade ≥3 adverse events occurred in 48.7% of HypoRT patients versus 67.7% of those in the conventional group, indicating a safer profile.
Expert opinion from Dr. Nan Bi of the Chinese Academy of Medical Sciences emphasized that hypofractionated radiotherapy offers a shorter, more manageable treatment course with fewer side effects, without compromising survival. This approach is particularly advantageous in settings where reducing treatment duration and toxicity is a priority, potentially improving patient quality of life and healthcare efficiency.
Further investigations are suggested to explore the combination of HypoRT with immunotherapy, which could harness immune-sparing benefits and improve therapeutic outcomes for lung cancer patients.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Study Reveals Brain's Body Map Remains Unchanged After Limb Amputation
New research uncovers that the brain's map of the body remains stable long after limb amputation, challenging previous beliefs about neural reorganization and opening new avenues for treatment and prosthetic control.
Innovative Rapid Diagnostic Technique Shortens Sepsis Detection to Hours
A novel diagnostic method accelerates sepsis detection from days to hours using microscale centrifugation and AI, enabling faster treatment and improving survival rates.
New Study Links Chemotherapy to Long-Term Cognitive Changes in Cancer Survivors
Recent research links chemotherapy to lasting cognitive changes in cancer survivors, highlighting molecular disruptions in the brain that may explain 'chemo brain' phenomena. Understanding these effects paves the way for targeted therapies to improve survivor outcomes.
Innovative Drug Shows Promise in Managing Resistant Hypertension
A new clinical trial highlights lorundrostat's potential to safely lower blood pressure in patients with resistant hypertension, marking a significant advancement in targeted hypertension therapy.